<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829140</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-014</org_study_id>
    <nct_id>NCT00829140</nct_id>
  </id_info>
  <brief_title>To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake</brief_title>
  <acronym>TULIP</acronym>
  <official_title>A 56-Day , Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake in Overweight and Obese Patients (TULIP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of lorcaserin on energy metabolism and
      food intake in obese and overweight patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of lorcaserin on 24h energy metabolism (measured in a respiratory chamber) after 56 days of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the ongoing safety of lorcaserin</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin 10mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin 10mg BID</intervention_name>
    <arm_group_label>Lorcaserin 10mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged between 18 and 65 years (inclusive)

          2. Body Mass Index (BMI) is 27.0 to 45.0 kg/m2, inclusive

          3. Able to give signed informed consent

          4. Ambulatory and able to perform exercise program (Arena Healthy Lifestyle Program, see
             Appendix 1)

          5. Eligible male and female patients must agree not to participate in a conception
             process

          6. Considered to be in stable health in the opinion of the Investigator

        Exclusion Criteria:

          1. Prior participation in any study of lorcaserin.

          2. Participants who are current smokers or have smoked within the previous 6 months. No
             smoking will be allowed during the study.

          3. Clinically significant new illness in the 1 month before screening

          4. Not suitable to participate in the study in the opinion of the Investigator including
             an existing physical or mental condition that prevents compliance with the protocol

          5. Recent history (within 6 months before entering the study) of major depression,
             anxiety, or other psychiatric disease requiring treatment with prescription
             medication. SSRI's, SNRI's, and other medications must meet washout requirements.

          6. Significant dislike or allergy to foods used during the food intake tests

          7. History of any of the following cardiovascular conditions:

               -  Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG),
                  CVA, TIA or RIND within 3 months of screening; cardiac arrhythmia requiring
                  medical or surgical treatment within 3 months of screening

               -  Unstable angina

               -  History of congestive heart failure caused by insufficiency, damage, or stenosis
                  of any heart valve

               -  History of pulmonary artery hypertension

          8. Positive result of HIV, hepatitis B or hepatitis C screens

          9. Recent treatment (i.e., within 1 month of the screening visit) with over-the-counter
             weight loss products or appetite suppressants (including herbal weight loss agents),
             or within 3 months with a prescription anti-obesity drug (e.g., phentermine,
             sibutramine, orlistat)

         10. Participated in any clinical study with an investigational drug, biologic, or device
             within 1 month prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Ravussin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christen Anderson MD, PhD</name_title>
    <organization>Arena Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

